<DOC>
	<DOC>NCT02280356</DOC>
	<brief_summary>The purpose of this study is to test the safety and side effects "of "ultra-hypofractionated" radiation therapy when used after brachytherapy (radiation implants). This treatment delivers a higher radiation dose with each treatment over a shorter period of time.</brief_summary>
	<brief_title>Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Intermediate risk prostate cancer patients will be eligible for this study. Intermediate risk grouping will be assessed per NCCN guidelines as: Pathologicallyproven diagnosis of prostate adenocarcinoma PSA 1020ng/mL or Gleason =7 or Clinical stage T2b/c Clinical stage T2b/c Additionally, patients will be required to meet the following criteria Age ≥18 KPS≥70 Prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). For patients with a prostate volume between 5060ccs, hormone therapy will be at the discretion of the physician. International Prostate Symptom Score ≤15 Prior prostate surgery (including TURP) Prior history of chronic prostatitis or urethral stricture Inflammatory bowel disease Prior history of pelvic radiotherapy Unable to give informed consent Metastatic disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiation Therapy</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>14-163</keyword>
</DOC>